JP2019521643A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521643A5
JP2019521643A5 JP2018554063A JP2018554063A JP2019521643A5 JP 2019521643 A5 JP2019521643 A5 JP 2019521643A5 JP 2018554063 A JP2018554063 A JP 2018554063A JP 2018554063 A JP2018554063 A JP 2018554063A JP 2019521643 A5 JP2019521643 A5 JP 2019521643A5
Authority
JP
Japan
Prior art keywords
polypeptide
variant
domain
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554063A
Other languages
English (en)
Japanese (ja)
Other versions
JP7527758B2 (ja
JP2019521643A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027817 external-priority patent/WO2017181152A2/en
Publication of JP2019521643A publication Critical patent/JP2019521643A/ja
Publication of JP2019521643A5 publication Critical patent/JP2019521643A5/ja
Priority to JP2022061863A priority Critical patent/JP2022109915A/ja
Priority to JP2024072025A priority patent/JP2024099752A/ja
Application granted granted Critical
Publication of JP7527758B2 publication Critical patent/JP7527758B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554063A 2016-04-15 2017-04-14 Ｃｄ８０バリアント免疫調節タンパク質およびその使用 Active JP7527758B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022061863A JP2022109915A (ja) 2016-04-15 2022-04-01 Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2024072025A JP2024099752A (ja) 2016-04-15 2024-04-26 Ｃｄ８０バリアント免疫調節タンパク質およびその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662323595P 2016-04-15 2016-04-15
US62/323,595 2016-04-15
US201662394743P 2016-09-14 2016-09-14
US62/394,743 2016-09-14
US201662410844P 2016-10-20 2016-10-20
US62/410,844 2016-10-20
US201762472570P 2017-03-16 2017-03-16
US62/472,570 2017-03-16
US201762475201P 2017-03-22 2017-03-22
US62/475,201 2017-03-22
PCT/US2017/027817 WO2017181152A2 (en) 2016-04-15 2017-04-14 Cd80 variant immunomodulatory proteins and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022061863A Division JP2022109915A (ja) 2016-04-15 2022-04-01 Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2024072025A Division JP2024099752A (ja) 2016-04-15 2024-04-26 Ｃｄ８０バリアント免疫調節タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2019521643A JP2019521643A (ja) 2019-08-08
JP2019521643A5 true JP2019521643A5 (OSRAM) 2020-05-21
JP7527758B2 JP7527758B2 (ja) 2024-08-05

Family

ID=59285316

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554063A Active JP7527758B2 (ja) 2016-04-15 2017-04-14 Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2022061863A Pending JP2022109915A (ja) 2016-04-15 2022-04-01 Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2024072025A Pending JP2024099752A (ja) 2016-04-15 2024-04-26 Ｃｄ８０バリアント免疫調節タンパク質およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022061863A Pending JP2022109915A (ja) 2016-04-15 2022-04-01 Ｃｄ８０バリアント免疫調節タンパク質およびその使用
JP2024072025A Pending JP2024099752A (ja) 2016-04-15 2024-04-26 Ｃｄ８０バリアント免疫調節タンパク質およびその使用

Country Status (12)

Country Link
US (5) US11078282B2 (OSRAM)
EP (1) EP3443000B1 (OSRAM)
JP (3) JP7527758B2 (OSRAM)
KR (3) KR20190006495A (OSRAM)
CN (1) CN109715657A (OSRAM)
AU (2) AU2017248830B2 (OSRAM)
CA (1) CA3019202A1 (OSRAM)
IL (2) IL262366B2 (OSRAM)
MA (1) MA43552A (OSRAM)
NZ (2) NZ787233A (OSRAM)
SG (1) SG11201808783XA (OSRAM)
WO (1) WO2017181152A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
KR20180069903A (ko) 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins and CD80 variants and their uses
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
SG11201903407XA (en) * 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
KR20250083578A (ko) * 2017-03-16 2025-06-10 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
IL320945A (en) 2017-10-18 2025-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
AU2019205273B2 (en) * 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
JP7605735B2 (ja) * 2018-09-05 2024-12-24 ポセイダ セラピューティクス，インコーポレイティド 同種異系細胞組成物およびその使用方法
JP2022501361A (ja) * 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用
US12378299B2 (en) 2019-04-26 2025-08-05 Xuanzhu Biopharmaceutical Co., Ltd. CD80 variant proteins and uses thereof
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy
TW202132342A (zh) * 2019-11-26 2021-09-01 大陸商北京軒義醫藥科技有限公司 T細胞活性的調節劑
JP2023517044A (ja) * 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
EP4122953A4 (en) * 2020-03-18 2023-08-23 GI Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
KR20230020501A (ko) 2020-06-03 2023-02-10 베링거 인겔하임 인터내셔날 게엠베하 CD80 세포외 도메인 Fc-융합 단백질을 인코딩하는 재조합 랍도바이러스
EP4490173A1 (en) * 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
US20250206801A1 (en) * 2022-04-02 2025-06-26 Hangzhou Sumgen Biotech Co., Ltd. Cd80 protein variant and cd80 fusion protein
CN114921431B (zh) * 2022-05-05 2023-04-25 湖北大学 糖基转移酶突变体及其在发酵生产芳香醇糖苷中的应用
CN119487059A (zh) * 2022-07-05 2025-02-18 杭州阿诺生物医药科技有限公司 一种cd80突变体多肽及其用途
CN114949000B (zh) * 2022-08-02 2022-10-04 卡瑞济(北京)生命科技有限公司 麝香提取物及其增强car-t细胞疗效的应用

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DE69233186T2 (de) 1991-05-06 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5942607A (en) 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
DE69519521T2 (de) 1994-10-03 2001-06-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
ES2317646T3 (es) 1995-09-08 2009-04-16 Genzyme Corporation Vectores aav mejorados para terapia genica.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
AU737910B2 (en) 1997-01-31 2001-09-06 Regents Of The University Of California, The Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1012236A1 (en) 1997-08-15 2000-06-28 Rubicon Laboratory Inc. Retrovirus and viral vectors
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US7446189B1 (en) 1999-04-30 2008-11-04 Institut De Recherches Cliniques De Montreal Nucleic acids encoding mutant human CD80 and compositions comprising the same
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
US6723316B2 (en) 1999-12-22 2004-04-20 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
JP4921669B2 (ja) 2000-01-21 2012-04-25 バイオヴェックス リミテッド ウイルス株
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20020164600A1 (en) 2000-06-28 2002-11-07 Gordon Freeman PD-L2 molecules: novel PD-1 ligands and uses therefor
PL212205B1 (pl) 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
GB0021976D0 (en) 2000-09-07 2000-10-25 Optomed As Multi-parameter fiber optic probes
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
US7122182B2 (en) 2001-05-11 2006-10-17 Wellstat Biologics Corporation Oncolytic virus therapy
EP1497426A2 (en) * 2001-06-22 2005-01-19 Maxygen, Inc. Co-stimulatory molecules
JP2004537305A (ja) 2001-07-11 2004-12-16 ユニバーシティー オブ マイアミ 腫瘍細胞の処置のための組換えｖｓｖ
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7247615B2 (en) 2001-11-30 2007-07-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptide agonists of prostate-specific antigen and uses therefor
US20040009604A1 (en) 2002-03-27 2004-01-15 Xiaoliu Zhang Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
AU2003243307B2 (en) 2002-06-21 2010-04-01 Wellstat Biologics Corporation Administration of therapeutic viruses
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20050260601A1 (en) 2002-09-09 2005-11-24 Whitt Michael A Recombinant mutants of rhabdovirus and methods of use thereof
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
DK1606411T3 (da) 2003-03-27 2009-03-30 Ottawa Health Research Inst Mutant vesikulær stomatitis-vira og anvendelse deraf
EP2028270B9 (en) 2003-06-18 2012-04-25 Genelux Corporation Modified recombinant vaccinia viruses, uses thereof
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP2275448A3 (en) 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2613310C (en) 2005-06-23 2014-06-17 Baylor College Of Medicine Use of mutant herpes simplex virus-2 for cancer therapy
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2008011636A2 (en) 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
GB2446721B (en) 2007-02-16 2009-03-25 Crusade Lab Ltd Herpes simplex viruses and methods of viral replication
DK2856876T3 (en) 2007-03-30 2018-04-03 Memorial Sloan Kettering Cancer Center Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes
US20090117034A1 (en) 2007-06-15 2009-05-07 Nanhai Chen Microorganisms for imaging and/or treatment of tumors
JP2010533649A (ja) 2007-07-13 2010-10-28 ザ ジョンズ ホプキンス ユニバーシティー Ｂ７−ｄｃ改変体
US20090162288A1 (en) 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
CN101925612A (zh) 2007-11-27 2010-12-22 维文蒂阿生物技术公司 针对癌相关的nfkbib变体的表位的抗体及其用途
TR201802323T4 (tr) 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
EP2300023A2 (en) 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8703120B2 (en) 2008-05-29 2014-04-22 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
US9283184B2 (en) 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
TR201819229T4 (tr) 2009-07-24 2019-01-21 Immune Design Corp Entegre olmayan lentiviral vektörler.
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
TWI496886B (zh) 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
EP3357511B1 (en) 2011-06-30 2020-05-13 Genzyme Corporation Inhibitors of t-cell activation
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
ES2707288T3 (es) 2012-03-30 2019-04-03 Immune Design Corp Partículas de vectores lentivíricos que tienen eficiencia de transducción mejorada para células que expresan DC-SIGN
JP6228971B2 (ja) 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
KR20150018604A (ko) 2012-06-06 2015-02-23 온코메드 파마슈티칼스, 인크. 히포 경로를 조절하는 결합제 및 그의 용도
JP5857896B2 (ja) 2012-07-06 2016-02-10 東京エレクトロン株式会社 成膜装置の運転方法及び成膜装置
CA2892831A1 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
HK1219740A1 (zh) 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
WO2014198002A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute A bacterium producing an interferon binding protein and uses thereof
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3835318B1 (en) 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
ES2792849T3 (es) 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
CA2955015A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
SG10201811841UA (en) 2014-07-16 2019-02-27 Genentech Inc Methods of treating cancer using tigit inhibitors and anti-cancer agents
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
KR20160021586A (ko) 2014-08-18 2016-02-26 지경민 시력교정용 필터 및 이를 이용한 시력교정방법
SG11201701506PA (en) 2014-09-03 2017-03-30 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
CN107207597A (zh) 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
EP3020816A1 (en) 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
WO2016118577A1 (en) 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
CN107708725A (zh) 2015-04-02 2018-02-16 坎库雷有限公司 用于引发免疫应答的剂和组合物
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
SI3328419T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
EP3328377A4 (en) 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
CA2993478A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
CA2995462A1 (en) 2015-08-12 2017-02-16 First Quality Packaging Solutions, Llc Container and method of forming the same
CN114767833A (zh) 2015-08-20 2022-07-22 弗劳恩霍夫应用研究促进协会 B7-h1融合多肽或多核苷酸用于治疗或预防肝衰竭的用途
MX2018003144A (es) 2015-09-14 2018-09-11 Alpine Immune Sciences Inc Dominios de superfamilia de inmunoglobulina de variante ajustable y terapia con células genéticamente modificadas.
MY190324A (en) 2015-10-02 2022-04-14 Symphogen As Anti-pd-1 antibodies and compositions
KR20180069903A (ko) 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
WO2017151818A2 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins and CD80 variants and their uses
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190019068A (ko) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
SG11201903407XA (en) 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
HUE064136T2 (hu) 2017-03-16 2024-02-28 Alpine Immune Sciences Inc PD-L1 variáns immunmódosító fehérjék és alkalmazásuk
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
KR20250083578A (ko) 2017-03-16 2025-06-10 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
JP2022501361A (ja) 2018-09-19 2022-01-06 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｃｄ８０融合タンパク質および関連構築物の方法および使用

Similar Documents

Publication Publication Date Title
JP2019521643A5 (OSRAM)
JP2019514361A5 (OSRAM)
CN112480253B (zh) 一种抗pd-l1纳米抗体及其衍生物和用途
EP3472205B1 (en) Chimeric antigen receptor
CN107406518B (zh) 嵌合抗原受体
JP2018512856A5 (OSRAM)
HRP20231382T1 (hr) Pd-l1 varijanta imunomodulacijskih proteina i njihova upotreba
JP2017537919A5 (OSRAM)
JP2016501535A5 (OSRAM)
JP2020529841A5 (OSRAM)
JP2020509776A5 (OSRAM)
JP2014519830A5 (OSRAM)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2020506898A5 (OSRAM)
CN105683215A (zh) 高稳定性的t细胞受体及其制法和应用
JP2018508219A5 (OSRAM)
JP2019516665A5 (OSRAM)
JP2013519721A5 (OSRAM)
JP2015212284A5 (OSRAM)
JP2003506028A (ja) キメラポリペプチド、その製造方法、およびその使用
JP2012507994A5 (OSRAM)
JP2019513394A5 (OSRAM)
CN105960412A (zh) 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
JP2018528786A5 (OSRAM)
EP3807311A1 (en) Serum albumin binding antibodies for tuneable half-life extension of biologics